These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 4199828)

  • 1. [Current status of experimental studies on Pseudomonas aeruginosa infection].
    Honma Y
    Nihon Saikingaku Zasshi; 1972 Sep; 27(5):629-40. PubMed ID: 4199828
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of pseudomonas respiratory infection in a surgical intensive care unit.
    Polk HC; Borden S; Aldrete JA
    Ann Surg; 1973 May; 177(5):607-15. PubMed ID: 4634109
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experimental infection of immunized mice homologous and heterologous serotypes with Pseudomonas aeruginosa].
    Vidal G; Mynard MC
    Ann Inst Pasteur (Paris); 1972 Jun; 122(6):1129-35. PubMed ID: 4627762
    [No Abstract]   [Full Text] [Related]  

  • 4. [Infections in minks caused by Pseudomonas aeruginosa. Infection and vaccination trials].
    Karlsson KA; Kull KE; Svanholm R
    Nord Vet Med; 1971; 23(7):345-51. PubMed ID: 5004400
    [No Abstract]   [Full Text] [Related]  

  • 5. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoserology of Pseudomonas aeruginosa infections in man. II. effect of natural and immune anti-LPS antibodies on pseudomonas colonization and infection.
    Petrás G; Adám MM; Lányi B; Konkoly Thege M; Szentmihályi A
    Acta Microbiol Hung; 1984; 31(2):101-8. PubMed ID: 6431739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 8. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa.
    Ding B; von Specht BU; Li Y
    Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigations on the immunogenicity of Pseudomonas seruginosa strains of different serological O-groups].
    Meitert E; Meitert T
    Zentralbl Bakteriol Orig; 1968; 208(4):515-21. PubMed ID: 5000090
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent investigations on Pseudomonas aeruginosa.
    Homma JY
    Jpn J Exp Med; 1971 Oct; 41(5):387-400. PubMed ID: 5002617
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoserology of Pseudomonas aeruginosa infections in man. I. Four types of interaction between host and bacterium.
    Petrás G; Adám MM; Lányi B; Szentmihályi A; Konkoly Thege M
    Acta Microbiol Hung; 1984; 31(2):91-100. PubMed ID: 6431740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live, attenuated vaccines against Pseudomonas: observations in the experimental animal and the human.
    Bellanti JA; Sordelli DO; Cerquetti MC; Wan KS; Arias G; Cereb N; Zuba D; Kulczycki L; Hooke AM
    Ann Sclavo Collana Monogr; 1986; 3(1-2):247-58. PubMed ID: 3122803
    [No Abstract]   [Full Text] [Related]  

  • 15. [Inhibition of generalization of wound infection in immunized rats].
    Pal'tsyn AA; Grishina IA; Kolokol'chikova EG; Chervonskaia NV; Badikova AK; Popova EP
    Biull Eksp Biol Med; 1994 May; 117(5):545-6. PubMed ID: 9296716
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pseudomonas infections in a hospital. 4. Type specific antibody in human serum].
    Shigeta S; Yasunaga Y
    Nihon Saikingaku Zasshi; 1976 Sep; 31(5):621-8. PubMed ID: 826672
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological and immunobiological implications of Pseudomonas aeruginosa epidemiological markers.
    Meitert T; Meitert E
    Arch Roum Pathol Exp Microbiol; 1981; 40(1):5-23. PubMed ID: 6821022
    [No Abstract]   [Full Text] [Related]  

  • 19. Pseudomonas aeruginosa vaccine in cancer patients.
    Young LS; Meyer RD; Armstrong D
    Ann Intern Med; 1973 Oct; 79(4):518-27. PubMed ID: 4201225
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.
    Cachia PJ; Hodges RS
    Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.